Dr. Markel is a senior medical oncologist, an associate professor at Sackler Faculty of Medicine at Tel Aviv University and the Chief Scientist of the Ella Lemelbaum Institute of Immuno-Oncology at Sheba Medical Center. He completed his PhD in Immunology in 2004 with highest honors, and his MD at 2005, both at the Hebrew University of Jerusalem, Israel.
Gal Markel is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology. He is the author of more than 90 peer-reviewed papers and the inventor of more than 20 patents. He co-founded BTC (acquired by DSPG in 2011) and was the scientific founder and Chief Scientific Officer of cCAM Biotherapeutics (acquired by Merck & Co in 2015). Dr. Markel is a highly active speaker and has given countless international talks, including TED MED, and has won many awards, such as from the Israel Cancer Association and the Wolf foundation. He is a co-founder, board member and the secretary of the Israel Association for Immuno-Oncology, and serves on the steering committee of the Israel Society for Cancer Research.